Source: NIST, National Institute of Standards and Technology

Source: NIST, National Institute of Standards and Technology

Principal Investigators

Dr Faisel Khan, Prof JD Hayes, Prof J Belch, et al.

Institution

Vascular & Inflammatory Diseases Research Unit, Division of Cardiovascular & Diabetes Medicine and Division of Cancer Research, Ninewells Hospital & Medical School, Dundee, UK

Funding

ME Research UK

Background and aim

Over the past decade, ME Research UK-funded researchers at the University of Dundee have uncovered a range of biological abnormalities in ME/CFS patients (see below), including high levels of apoptotic (dying) white blood cells and increased arterial stiffness. Their main finding, however, has been that people with ME/CFS have high levels of reactive oxygen molecules, which can harm blood vessels and muscles. These molecules are formed in the body during biological processes that use oxygen, such as exercise. In healthy people they are counter-balanced by antioxidants that detoxify the oxygen molecules to prevent damage, but sometimes an imbalance can lead to increased ‘oxidative stress’ and an increased risk of cardiovascular disease.

It is important to discover the origin of these molecules, so that ways of counteracting oxidative stress-related cardiovascular damage can be developed. For this reason, the research team in Dundee has received funding from ME Research UK to investigate the role of ‘nuclear factor erythroid-derived 2’ (Nrf2). This is an extremely important regulatory protein in the body, and is now believed to be a master activator of the body’s natural defence against oxidative stress. When reactive oxygen species are generated, Nrf2 is activated, stimulating the body’s antioxidant pathways and thereby providing a buffer against oxidative stress.

The researchers’ aim is to test whether Nrf2 activity is low (in quantity and in gene expression) in blood samples from ME/CFS patients, and whether Nrf2 levels are related to levels of oxidative stress. Importantly, the team will also examine whether the Nrf2 antioxidant system of ME/CFS patients can be activated by certain foodstuffs and by some therapeutic drugs. At present, several drugs that stimulate the Nrf2 pathway are being assessed as treatments for other diseases, including multiple sclerosis in which oxidative stress is involved, but this is the first time ME/CFS patients have been studied.

During the 18-month study, blood samples will be taken from 40 ME/CFS patients in the unit headed by Professor Julia Newton in Newcastle, and from age and sex-matched control subjects recruited from the general population. A range of assays will be undertaken in the laboratories at the University of Dundee, including for oxidative stress and Nrf2 protein levels (by Western blotting), and for the expression of Nrf2-target genes (by real-time PCR). An important part of the experiment is to examine whether Nrf2 target genes can be induced in white blood cells by dietary components and/or therapeutic drugs, and whether oxidative stress is affected. Accordingly, the researchers will treat white blood cells from patients and controls with various doses of dietary compounds that activate Nrf2, and with some therapeutic agents.

If low Nrf2 levels are found to play a central role in the increased oxidative stress found in ME/CFS patients, stimulation of Nrf2 could become an important treatment strategy, as there are currently no specifically effective treatments for the illness. The findings may also have broader implications for studies of Nrf2-targetted treatments in other conditions characterised by elevated oxidative stress, such as cancer, diabetes and liver disease.

Research at the University of Dundee

In modern science, real breakthroughs come at the end of a programme of painstaking work by a specialist group of researchers. One of the few examples of such a programme on ME/CFS, anywhere in the world, is the work at the Vascular Diseases Research Unit, University of Dundee. This group has received a number of grants from ME Research UK in the past 13 years. In a step-by-step progression involving both adults and young people with the illness, the group has discovered:

  • Unusual sensitivity of blood flow to acetylcholine (a neurotransmitter) – Link
  • Increased levels of isoprostanes (a gold standard marker of oxidative stress in the bloodstream) – Link
  • An unexpected increase in dying (apoptotic) white blood cells, consistent with an activated inflammatory process or persistent infection – Link
  • Increased cardiovascular risk factors with arterial stiffness in patients – Link
  • Biochemical anomalies in children mirroring those found in adults with the illness – Link
  • Dysfunction of the vascular endothelium (the lining of blood vessels) – Link
  • An association between vitamin D and markers of cardiovascular risk – Link

Further reading

Nrf2 activation as target to implement therapeutic treatments. Frontiers in Chemistry, 2015
The clinical potential of influencing Nrf2 signaling in degenerative and immunological disorders. Clinical Pharmacology, 2014.
Nrf2, a multi-organ protector? The FASEB Journal, 2005